Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Cited by (1,021)

Items 501–600 of 1,021

1. Dabrafenib and its potential for the treatment of metastatic melanoma
   Rajmohan Murali, Alexander Maxwell Menzies, Georgina Venetia Long · 2012 · Drug Design Development and Therapy
2. Nivolumab in melanoma: latest evidence and clinical potential
   Douglas Buckner Johnson, Chengwei Peng, Jeffrey Alan Sosman · 2015 · Therapeutic Advances in Medical Oncology
3. Advances in immunotherapy for melanoma
   Jason Mark Redman, Geoffrey Thomas Gibney, Michael B. Atkins · 2016 · BMC Medicine
4. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
   Chan Kim, Eun‐Kyung Kim, Hun Jung, Hong Jae Chon, Jung Woo Han, Kyoo-Ho Shin, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sung‐Hoon Kim et al. · 2016 · BMC Cancer
5. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors
   Malidi Ahamadi, Tomoko Freshwater, Marita Prohn, Claire H. Li, DP de Alwis, Rik de Greef, Jeroen Elassaiss‐Schaap, Anna Georgieva Kondic, JA Stone · 2016 · CPT Pharmacometrics & Systems Pharmacology
6. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
   Kimbara, Shiro, Fujiwara, Yutaka, Iwama, Shintaro, Ohashi, Ken, Kuchiba, Aya, Arima, Hiroshi, Yamazaki, Naoya, Kitano, Shigehisa, Yamamoto, Noboru, Ohe, Yuichiro · 2018 · Cancer Science
7. PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
   Jason J. Luke, Patrick Alexander Ott · 2015 · Oncotarget
8. HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells
   Roberta Santini, Maria Cristina Vinci, Silvia Pandolfi, Junia Yara Penachioni, Valentina Montagnani, Biagio Olivito, Riccardo Gattai, Nicola Pimpinelli, Gianni Gerlini, Lorenzo Borgognoni et al. · 2012 · Stem Cells
9. Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
   Evan J. Lipson, Mabel A. Bodell, Edward S. Kraus, William Howard Sharfman · 2014 · Journal of Clinical Oncology
10. Mechanisms and Therapy for Cancer Metastasis to the Brain
    Federica Franchino, Roberta Rudà, Riccardo Soffietti · 2018 · Frontiers in Oncology
11. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
    Michele Del Vecchio, Lorenza Di Guardo, Paolo A. Ascierto, Antonio Maria Grimaldi, Vanna Chiarion‐Sileni, Jacopo Pigozzo, Virginia Ferraresi, Carmen M. A. Nuzzo, Gaetana Rinaldi, Alessandro Testori et al. · 2013 · European Journal of Cancer
12. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype
    Daniel Hirschhorn-Cymerman, Sadna Budhu, Shigehisa Kitano, Cailian Liu, Feng Zhao, Hong Zhong, Alexander M. Lesokhin, Francesca Avogadri-Connors, Jianda D. Yuan, Yanyun Li et al. · 2012 · The Journal of Experimental Medicine
13. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone
    Kristian Michael Koller, Heath B. Mackley, Jason Liu, Henry Wagner, Giampaolo Talamo, Todd D. Schell, Colette Pameijer, Rogerio Izar Neves, Bryan E. Anderson, Kathleen M. Kokolus et al. · 2016 · Cancer Biology & Therapy
14. Melanoma, Version 2.2013
    Daniel G. Coit, Robert H.I. Andtbacka, Christopher James Anker, Christopher Keram Bichakjian, William Edgar Carson, ADIL I. DAUD, Dominick J. DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern et al. · 2013 · Journal of the National Comprehensive Cancer Network
15. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
    Clélia Coutzac, Julien Adam, Émilie Soularue, Michael Collins, Antoine Racine, Charlotte Mussini, Lisa Boselli, Nyam Kamsu-Kom, Christine Mateus, Mélinda Charrier et al. · 2017 · Journal of Crohn s and Colitis
16. Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
    Cuende, Julia, Liénart, Stéphanie, Dedobbeleer, Olivier, van der Woning, Bas, De Boeck, Gitte, Stockis, Julie, Huygens, Caroline, Colau, Didier, Somja, Joan, Delvenne, Philippe et al. · 2015 · Science Translational Medicine
17. MAP kinase signaling and inhibition in melanoma
    Ryan Joseph Sullivan, Keith T. Flaherty · 2012 · Oncogene
18. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
    Bernice Lo, Jill M. Fritz, Helen C. Su, Gülbû Uzel, Michael B. Jordan, Michael J. Lenardo · 2016 · Blood
19. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
    Julia Zaragoza, Agnès Caille, N. Bénéton, Guido Bens, François Christiann, H. Maillard, L. Machet · 2015 · British Journal of Dermatology
20. Inhibitory receptors as targets for cancer immunotherapy
    Meghan E. Turnis, Lawrence Peter Andrews, Dario A.A. Vignali · 2015 · European Journal of Immunology
21. Checkpoint inhibitors in breast cancer – Current status
    Anne Dyhl-Polk, Inge Marie Svane, Michael Andersson, Dorte Lisbet Nielsen · 2017 · Cancer Treatment Reviews
22. Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
    Xin Lin, Xiang Lu, Guoshun Luo, Hua Xiang · 2019 · European Journal of Medicinal Chemistry
23. Endogenous retroviruses in the origins and treatment of cancer
    Natasha Jansz, Geoffrey J. Faulkner · 2021 · Genome biology
24. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
    Thiem, Alexander, Hesbacher, Sonja, Kneitz, Hermann, di Primio, Teresa, Heppt, Markus V., Hermanns, Heike M., Goebeler, Matthias, Meierjohann, Svenja, Houben, Roland, Schrama, David · 2019 · Journal of Experimental & Clinical Cancer Research
25. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma
    Sebastian Theurich, Sacha I. Rothschild, Michael Hoffmann, Mario Fabri, Andrea Sommer, Maria Alejandra Garcia-Marquez, Martin Thelen, Catherine Schill, Ramona Merki, Thomas Schmid et al. · 2016 · Cancer Immunology Research
26. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
    Michael Collins, Jean‐Marie Michot, F.X. Danlos, Charlotte Mussini, Émilie Soularue, Christine Mateus, Delphine Loirat, Anthony Buisson, Isabelle Rosa, Olivier Lambotte et al. · 2017 · Annals of Oncology
27. Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
    Caroline Robert, Dirk Schadendorf, MARIANNE E. MESSINA, Frank Stephen Hodi, Steven J O'Day · 2013 · Clinical Cancer Research
28. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma
    John F. Thompson, Sanjiv S. Agarwala, Bernard Mark Smithers, Merrick I. Ross, Charles Raben Scoggins, Brendon John Coventry, Susan J. Neuhaus, David R. Minor, Jamie M. Singer, Eric Andrew Wachter · 2014 · Annals of Surgical Oncology
29. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
    Alexander M. Lesokhin, Margaret K. Callahan, Michael Andrew Postow, Jedd D. Wolchok · 2015 · Science Translational Medicine
30. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
    Neeraj Chhabra, Joseph M. Kennedy · 2021 · Journal of Medical Toxicology
31. Cardiotoxicity of Immune Checkpoint Inhibitors
    Rushin P. Patel, Rohan B. Parikh, Krishna Soujanya Gunturu, Rana Zouveenoor Tariq, Sourbha S. Dani, Sarju Ganatra, Anju Nohria · 2021 · Current Oncology Reports
32. Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
    Lucy Lee, Manish Gupta, Srikumar Sahasranaman · 2015 · The Journal of Clinical Pharmacology
33. Cancer, Inflammation, and Therapy: Effects on Cytochrome P450–Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents
    Robert Donald Harvey, Edward T. Morgan · 2014 · Clinical Pharmacology & Therapeutics
34. Harnessing the Power of the Immune System to Target Cancer
    Gregory A. Lizee, Willem W. Overwijk, Laszlo George Radvanyi, Jianjun Gao, Padmanee Sharma, Patrick Hwu · 2012 · Annual Review of Medicine
35. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
    Harriet M. Kluger, Christopher R. Zito, Gabriela Turcu, Marina K. Baine, Hongyi Zhang, Adebowale Adeniran, Mario Sznol, David L. Rimm, Yuval Kluger, Lieping Chen et al. · 2017 · Clinical Cancer Research
36. CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation
    Shunsuke Chikuma · 2017 · Current topics in microbiology and immunology
37. Anti–CTLA-4 therapy requires an Fc domain for efficacy
    Jessica R. Ingram, Olga S. Blomberg, Mohammad Rashidian, Lestat R. Ali, S. Garforth, E.V. Fedorov, Alexander A. Fedorov, J.B. Bonanno, Camille M. Le Gall, Stephanie J. Crowley et al. · 2018 · Proceedings of the National Academy of Sciences
38. Melanoma central nervous system metastases: current approaches, challenges, and opportunities
    Justine Vanessa Cohen, Hussain Tawbi, Kim Allyson Margolin, Ravi Amravadi, Marcus Bosenberg, Priscilla Kaliopi Brastianos, Veronica Chiang, John de Groot, Isabella C. Glitza, Meenhard Herlyn et al. · 2016 · Pigment Cell & Melanoma Research
39. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma
    Gongjian Zhu, Haixiang Su, Caroline Helen Johnson, Sajid Ali Khan, Harriet M. Kluger, Lingeng Lu · 2021 · European Journal of Cancer
40. Trial Watch
    Erika Vacchelli, Fernando Aranda, Alexander M.M. Eggermont, Jérôme Galon, Catherine Sautès‐Fridman, Isabelle Cremer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2014 · OncoImmunology
41. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
    Matteo Santoni, Alessandro Rizzo, Jakub Kucharz, Veronica Mollica, Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, Fernando Sabino Marques Monteiro, Andrey Soares, Javier Molina‐Cerrillo et al. · 2023 · Cancer Immunology Immunotherapy
42. Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
    Nadeem Riaz, Jonathan J. Havel, Sviatoslav M. Kendall, Vladimir Makarov, Logan A. Walsh, Alexis Desrichard, Nils Weinhold, Timothy An-thy Chan · 2016 · Nature Genetics
43. Immune checkpoint inhibitors in cancer therapy
    S. Eika, Liu Peng, Renato B. Baleeiro, R. Nicholas, Yuan Ming, Wang Yaohe · 2017 · Journal of Biomedical Research
44. Regulatory T Cells in Cancer
    Plitas, George, Rudensky, Alexander Y. · 2020 · Annual Review of Cancer Biology
45. Immune modulation for cancer therapy
    Jarushka Naidoo, David B. Page, Jedd D. Wolchok · 2014 · British Journal of Cancer
46. Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
    David Erwin Kleiner, David Berman · 2012 · Digestive Diseases and Sciences
47. Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
    Ahmad A. Tarhini, John Cherian, Stergios J. Moschos, Hussein A. Tawbi, Yongli Shuai, William E. Gooding, Cindy Sander, John M. Kirkwood · 2011 · Journal of Clinical Oncology
48. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino, Gerardo Botti, Paul C. Lorigan, Giuseppe Valentino Masucci, Jason Hipp, Christine E. Horak, Ignacio Melero, Paolo A. Ascierto · 2016 · Drugs
49. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study
    Christos Sachpekidis, Lionel Larribère, Leyun Pan, Uwe Haberkorn, Antonia Dimitrakopoulou‐Strauss, Jessica C. Hassel · 2014 · European Journal of Nuclear Medicine and Molecular Imaging
50. Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
    Christopher Andrew Barker, Michael Andrew Postow, Shaheer A. Khan, Kathryn P. Beal, Preeti K. Parhar, Yoshiya Josh Yamada, Nancy Y. Lee, Jedd D. Wolchok · 2013 · Cancer Immunology Research
51. Armed oncolytic viruses: A kick-start for anti-tumor immunity
    J. Fréderique de Graaf, Lisanne de Vor, Ron A. M. Fouchier, Bernadette G. van den Hoogen · 2018 · Cytokine & Growth Factor Reviews
52. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
    Ott, Patrick A., Carvajal, Richard D., Pandit-Taskar, Neeta, Jungbluth, Achim A., Hoffman, Eric W., Wu, Bor-Wen, Bomalaski, John S., Venhaus, Ralph, Pan, Linda, Old, Lloyd J. et al. · 2013 · Investigational New Drugs
53. The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.
    Jack McCain · 2013 · Europe PMC (PubMed Central)
54. The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
    Kira Minkis, Benjamin C. Garden, Shenhong Wu, Melissa P. Pulitzer, Mario E. Lacouture · 2013 · Journal of the American Academy of Dermatology
55. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
    Rikke Holmgaard, Dmitriy Zamarin, Alexander M. Lesokhin, Taha Merghoub, Jedd D. Wolchok · 2016 · EBioMedicine
56. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis of published data
    Wenjun Wang, Puyi Lie, Minzhang Guo, Jianxing He · 2017 · International Journal of Cancer
57. Chemotherapy in the management of advanced cutaneous malignant melanoma
    Jason J. Luke, Gary K. Schwartz · 2013 · Clinics in Dermatology
58. Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
    Florian Wimmers, Gerty Schreibelt, Annette E. Sköld, Carl Gustav Figdor, I. Jolanda M. de Vries · 2014 · Frontiers in Immunology
59. Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
    Willem Joost Lesterhuis, Joanne Salmons, Anna K. Nowak, Esdy N. Rozali, Andrea Khong, Ian M. Dick, Julie A. Harken, Bruce W. S. Robinson, Richard Lake · 2013 · PLoS ONE
60. Risk of Endocrine Complications in Cancer Patients Treated with Immune Check Point Inhibitors: A Meta-Analysis
    Omar Mohammed Abdel-Rahman, Hesham M. Elhalawani, Mona Fouad · 2016 · Future Oncology
61. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
    Michael B. Atkins, Joseph I. Clark, David I. Quinn · 2017 · Annals of Oncology
62. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
    Eduard Cornelis Verschuren, Alfons J.M. van den Eertwegh, Janneke Wonders, Rob M.E. Slangen, Foke van Delft, Adriaan Anthonie Van Bodegraven, Andra Neefjes‐Borst, Nanne K.H. de Boer · 2015 · Clinical Gastroenterology and Hepatology
63. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
    Max S. Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Yanina Jeanne Leona Jansen, Inès Chevolet, Ambre Bott, Sofie Wilgenhof, Teofila Seremet, Bart Jacobs, Ronald Buyl et al. · 2016 · Journal of Translational Medicine
64. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
    Yung‐Jue Bang, Y. Choi, Yeul Hong Kim, Jin Won Kim, Maria Di Bartolomeo, Jaffer A. Ajani, Kensei Yamaguchi, Ágnes Balogh, Teresa Sánchez, Markus Hermann Moehler · 2017 · Clinical Cancer Research
65. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer
    Daniela Cornelia Lazăr, Mihaela Flavia Avram, Ioan Romosan, Mărioara Cornianu, Sorina Maria Tăban, Adrian Goldiș · 2018 · World Journal of Gastroenterology
66. Hallmarks of Resistance to Immune-Checkpoint Inhibitors
    Maria Karasarides, Alexandria P. Cogdill, Paul B. Robbins, Michaela Bowden, Elizabeth M. Burton, Lisa Helene Butterfield, Alessandra Cesano, Christian Hammer, Cara Haymaker, Christine E. Horak et al. · 2022 · Cancer Immunology Research
67. Prospects for combining immune checkpoint blockade with PARP inhibition
    Li, Anping, Yi, Ming, Qin, Shuang, Chu, Qian, Luo, Suxia, Wu, Kongming · 2019 · Journal of Hematology & Oncology
68. A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
    Thomas Eigentler, Benjamin Weide, Filippo de Braud, Gianluca Spitaleri, Antonella Romanini, Annette Pflugfelder, Reinerio González‐Iglesias, Annaelisa Tasciotti, Leonardo Giovannoni, Kathrin Schwager et al. · 2011 · Clinical Cancer Research
69. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies
    Célèste Lebbé, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Omid Hamid, Steven J O'Day, Cyril Konto, Lori Cykowski, M. Brent McHenry et al. · 2014 · Annals of Oncology
70. CD4 + CD25 + regulatory T cells in tumor immunity
    Xin Chen, Yong Du, Xiuqing Lin, Yan Qian, Ting Zhou, Zhiming Huang · 2016 · International Immunopharmacology
71. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
    Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Devin C. Dressman, Antonios Papanicolau‐Sengos, Blake Burgher, Jonathan Andreas, Vincent Giamo et al. · 2018 · Journal for ImmunoTherapy of Cancer
72. DNAM‐1 control of natural killer cells functions through nectin and nectin‐like proteins
    Lucas Ferrari de Andrade, Mark John Smyth, Ludovic Martinet · 2013 · Immunology and Cell Biology
73. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection
    Shohei Eto, Kozo Yoshikawa, Masaaki Nishi, Jun Higashijima, Takuya Tokunaga, Toshihiro Nakao, Hideya Kashihara, Chie Takasu, Takashi Iwata, Mitsuo Shimada · 2015 · Gastric Cancer
74. Immune targeting in breast cancer.
    Ashley Cimino‐Mathews, Jeremy B. Foote, Leisha A. Emens · 2015 · PubMed
75. Current Advances in T-Cell-Based Cancer Immunotherapy
    Mingjun Wang, Bingnan Yin, Helen Y. Wang, Rong‐Fu Wang · 2014 · Immunotherapy
76. Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer
    Xin Jin, Zhaorui Liu, Dongxiao Yang, Kai Yin, Xusheng Chang · 2022 · Frontiers in Immunology
77. Immune-mediated mechanisms influencing the efficacy of anticancer therapies
    Seth B. Coffelt, Karin E. de Visser · 2015 · Trends in Immunology
78. Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges
    Nancy Alice Nixon, Normand Blais, Scott Ernst, Christian Kollmannsberger, Gwyn D. Bebb, Marcus Otho Butler, Michael Smylie, Sunil Verma · 2018 · Current Oncology
79. Advances in targeted therapy for malignant lymphoma
    Li Wang, Wei Dong Qin, Yujia Huo, Xiao Li, Qing Shi, John E. J. Rasko, Anne Janin, Weili Zhao · 2020 · Signal Transduction and Targeted Therapy
80. Treatment of NRAS-mutant melanoma
    Johnson, Douglas B., Puzanov, Igor · 2015 · Current Treatment Options in Oncology
81. Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1α-Dependent Phenotype Switching
    Daniel S. Widmer, Keith Sean Hoek, Phil Fang Cheng, Ossia M. Eichhoff, Thomas Biedermann, Marieke I.G. Raaijmakers, Silvio Hemmi, Reinhard Dummer, Mitchell Paul Levesque · 2013 · Journal of Investigative Dermatology
82. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.
    Chris Fellner · 2012 · Europe PMC (PubMed Central)
83. Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
    Paolo A. Ascierto, Michael D. Kalos, David Schaer, Margaret K. Callahan, Jedd D. Wolchok · 2013 · Clinical Cancer Research
84. The expanding role for small molecules in immuno-oncology
    Rienk Offringa, Lisa Kötzner, Bayard R. Huck, Klaus Urbahns · 2022 · Nature Reviews Drug Discovery
85. Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
    Maarten Swart, Inge Verbrugge, Joost B. Beltman · 2016 · Frontiers in Oncology
86. Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
    Triparna Sen, Carl Michael Gay, Lauren A. Byers · 2018 · Translational Lung Cancer Research
87. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
    Diana Llópiz, Marta Ruiz, Lorea Villanueva, Tamara Iglesias, Leyre Silva, Josune Egea, Juan José Lasarte, Perrine Pivette, Véronique Trochon-Joseph, Bérangère Vasseur et al. · 2018 · Cancer Immunology Immunotherapy
88. Prognostic and predictive markers for the new immunotherapies.
    Kathleen Margaret Mahoney, Michael B. Atkins · 2014 · PubMed
89. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
    Anna Maria Di Giacomo, Paolo A. Ascierto, Paola Queirolo, Lorenzo Pilla, Ruggero Ridolfi, Mario Santinami, Alessandro Testori, Ester Simeone, Massimo Guidoboni, Andrea Maurichi et al. · 2014 · Annals of Oncology
90. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects
    Yuval Shaked · 2016 · Nature Reviews Clinical Oncology
91. Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
    Leandro Machado Colli, Mitchell J. Machiela, Timothy A. Myers, Lea Jessop, Kai F. Yu, Stephen Jacob Chanock · 2016 · Cancer Research
92. Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma
    June YiJuan Hou, Caitlin D. Baptiste, Radhika Bangalore Hombalegowda, Ana Isabel Tergas, Rebecca A. Feldman, Nathaniel Jones, Sudeshna Chatterjee‐Paer, Ama Bus‐Kwolfski, Jason Dennis Wright, William M. Burke · 2016 · Cancer
93. Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies
    Gianfranco Mattia, Rossella Puglisi, Barbara Ascione, Walter Malorni, Alessandra Carè, Paola Matarrese · 2018 · Cell Death and Disease
94. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 Mg/Kg within an expanded access programme
    Di Giacomo, Anna Maria, Calabrò, Luana, Danielli, Riccardo, Fonsatti, Ester, Bertocci, Erica, Pesce, Isabella, Fazio, Carolina, Cutaia, Ornella, Giannarelli, Diana, Miracco, Clelia et al. · 2013 · Cancer Immunology Immunotherapy
95. IFN-α in the Treatment of Melanoma
    Ahmad A. Tarhini, Helen J Gogas, John M. Kirkwood · 2012 · The Journal of Immunology
96. Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
    Jianda D. Yuan, Jun Min Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S. Panageas, Phillip Wong, Xinqi Wu, Jarushka Naidoo, David B. Page et al. · 2014 · Cancer Immunology Research
97. Recent Advances and Challenges in Cancer Immunotherapy
    Chelsea M. Peterson, Nathan Denlinger, Yiping Yang · 2022 · Cancers
98. Transient MEK inhibitor-associated retinopathy in metastatic melanoma
    Ursula Urner-Bloch, Martin Urner, P. Stieger, N. Galliker, Nina Winterton, Angela Zubel, Laure Moutouh–de Parseval, Reinhard Dummer, Simone M. Goldinger · 2014 · Annals of Oncology
99. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
    Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, Michael J. Evans, Junnian Wei, Yung-Hua Wang, Mingyi Chen, John Huang, Chanhyuk Park, Anthony Chang et al. · 2018 · Journal of Clinical Investigation
100. Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
     Shigehisa Kitano, Takemasa Tsuji, Caillian Liu, Daniel Hirschhorn-Cymerman, Chrisann Kyi, Zhenyu Mu, James Patrick Allison, Sacha Gnjatic, Jianda D. Yuan, Jedd D. Wolchok · 2013 · Cancer Immunology Research